Dermatology · Autoimmune DiseaseTrial Updateclinicalmid-term

Regeneron and Sanofi Study Dupilumab for Bullous Pemphigoid in Adults

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/20/2026, 12:31:12 PM

Assessment confidence: 59% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing trial of dupilumab for bullous pemphigoid represents a significant opportunity for Regeneron and Sanofi to expand their portfolio in the autoimmune disease space. Success could not only enhance their market presence but also influence treatment paradigms in dermatology. Regulatory context from FDA (FDA AP — DUPIXENT (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (3 high-relevance).

Strategic Assessment

Success in this trial may expand Regeneron and Sanofi's portfolio in autoimmune diseases, enhancing their market presence. The strongest clinical anchor is A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut (ClinicalTrials.gov), sub-indication match (immunology). In immunology, 2 regulatory and 3 competitive items passed relevance filtering for Regeneron.

Competitive Pressure

The most relevant competitive pressure comes from Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 (Bristol Myers Squibb) — sub-indication match (immunology); sponsor/company relevance (bristol myers squibb). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DUPIXENT (SUPPL) (FDA). Entity match (regeneron); Regulatory pathway relevance (bla). The trial's outcomes will inform future regulatory submissions and labeling for dupilumab, impacting its approval and positioning in the treatment of bullous pemphigoid.

Key Risks

Elevated medium regulatory exposure for Regeneron could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, dupilumab could capture a niche market, potentially increasing revenue and market share in the autoimmune segment, while also affecting competitors in dermatology.
Upside for Regeneron may improve if Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. (PubMed) delivers favorable follow-through.
Success in this trial may expand Regeneron and Sanofi's portfolio in autoimmune diseases, enhancing their market presence.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for efficacy and safety data, as well as any impact on corticosteroid use in patients.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DUPIXENT (SUPPL)
FDAmedium relevance
Entity match (regeneron); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — DUPIXENT (SUPPL)
FDAmedium relevance
Entity match (regeneron); Regulatory pathway relevance (bla)
FDA document
View source
Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Sub-indication match (immunology)
FDA document
View source
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
ClinicalTrials.govmedium relevance
Sub-indication match (immunology)
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
ClinicalTrials.govmedium relevance
Entity match (regeneron)
FDA document
View source
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cohort Study on Neuroimmune Diseases in the Reproductive Age
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
Bristol Myers Squibbhigh relevance
Sub-indication match (immunology); Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sub-indication match (immunology); Sponsor/company relevance (Roche)
[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerlow relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
PubMedhigh relevance
Sub-indication match (immunology); Entity match (dupilumab)
FDA document
View source
Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety and immunogenicity of a booster dose of COVAC-2, Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre tria
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Regeneron
Sanofi
dupilumab

Commercial impact

medium

If successful, dupilumab could capture a niche market, potentially increasing revenue and market share in the autoimmune segment, while also affecting competitors in dermatology.

Regulatory impact

medium

The trial's outcomes will inform future regulatory submissions and labeling for dupilumab, impacting its approval and positioning in the treatment of bullous pemphigoid.

What to watch

Monitor trial results for efficacy and safety data, as well as any impact on corticosteroid use in patients.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.